Clinical trials in Nantes – page 14

954 clinical trials in Nantes, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Nantes at a glance

954

clinical trials

Research sites2

Quick filters

954 trials in Nantes

Open in trial search

Urethral valves

Recruiting

Study on the Effectiveness and Safety of Circumcision and Antibiotic Treatment (Cefaclor, Sulfamethoxazole, Trimethoprim) for Boys with Posterior Urethral Valves

Registered drugNo placebo

Study on the Effectiveness and Safety of Circumcision and Antibiotic Treatment (Cefaclor, Sulfamethoxazole, Trimethoprim) for Boys with Posterior Urethral Valves

Registered drugNo placebo

France

Participants:0–17 years
Substances:Amoxicillin
Sponsor:Centre Hospitalier Universitaire De Bordeaux

Contact Research Centre

Hepatoblastoma+1

Recruiting

Study on the Safety and Effectiveness of Patritumab Deruxtecan for Children with Relapsed or Refractory Hepatoblastoma and Rhabdomyosarcoma

Registered drugNo placebo

Study on the Safety and Effectiveness of Patritumab Deruxtecan for Children with Relapsed or Refractory Hepatoblastoma and Rhabdomyosarcoma

Registered drugNo placebo

France

Participants:0–17 years
Substances:Dexamethasone
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Peripheral T-cell lymphoma unspecified+1

Recruiting

Study on Azacitidine, Roginolisib, and Golcadomide for Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas

Registered drugNo placebo

Study on Azacitidine, Roginolisib, and Golcadomide for Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:LYSARC

Contact Research Centre

Heart failure with reduced ejection fraction

Recruiting

Study of Omecamtiv Mecarbil for Treating Patients with Chronic Heart Failure and Severely Reduced Heart Pumping Ability

Investigational

Study of Omecamtiv Mecarbil for Treating Patients with Chronic Heart Failure and Severely Reduced Heart Pumping Ability

Investigational

France

Participants:18–64 years · 65+ years
Substances:Omecamtiv mecarbil
Sponsor:Cytokinetics Inc.

Contact Research Centre

Blastic plasmacytoid dendritic cell neoplasia

Recruiting

Study on the Effectiveness and Safety of Tagraxofusp and Venetoclax for Adults with Untreated Blastic Plasmacytoid Dendritic Cell Neoplasm

Registered drugNo placebo

Study on the Effectiveness and Safety of Tagraxofusp and Venetoclax for Adults with Untreated Blastic Plasmacytoid Dendritic Cell Neoplasm

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Tagraxofusp
Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Contact Research Centre

Subarachnoid haemorrhage

Recruiting

Study of cilostazol and nimodipine combination to improve outcomes in patients with aneurysmal subarachnoid hemorrhage

Registered drug

Study of cilostazol and nimodipine combination to improve outcomes in patients with aneurysmal subarachnoid hemorrhage

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Cilostazol
Sponsor:Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience

Contact Research Centre

Plasma cell myeloma

Recruiting

Study of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients

Registered drugNo placebo

Study of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Intergroupe Francophone Du Myelome

Contact Research Centre

Oesophageal cancer metastatic+3

Recruiting

Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo

Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Infection prophylaxis

Recruiting

Study on Preventing Infections in ICU Patients with Interferon Gamma and Sodium Chloride

Registered drug

Study on Preventing Infections in ICU Patients with Interferon Gamma and Sodium Chloride

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Sodium Chloride
Sponsor:Centre Hospitalier Et Universitaire De Limoges

Contact Research Centre

Relapsing-remitting multiple sclerosis

Recruiting

Study on Anti-CD20 Therapy and Drug Combination for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo

Study on Anti-CD20 Therapy and Drug Combination for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Dimethyl Fumarate
Sponsor:Centre Hospitalier Universitaire De Montpellier

Contact Research Centre

Mantle cell lymphoma

Recruiting

Study on the Effectiveness and Safety of Sonrotoclax and Zanubrutinib for Adults with Relapsed or Refractory Mantle Cell Lymphoma

Investigational

Study on the Effectiveness and Safety of Sonrotoclax and Zanubrutinib for Adults with Relapsed or Refractory Mantle Cell Lymphoma

Investigational

France

Participants:18–64 years · 65+ years
Substances:Zanubrutinib
Sponsor:BeOne Medicines AG

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Nantes

What the registry says about research in the country

01 Oncology and Hematology

Advanced research focusing on multiple myeloma, leukemia, and various lymphomas. Studies are evaluating novel treatment combinations and therapeutic approaches for blood cancers.

Multiple Myeloma Treatments
Lymphoma Therapies
Leukemia Management

Innovative trials exploring combinations of targeted therapies and immunotherapies to improve patient outcomes.

02 Infectious Diseases

Comprehensive studies on preventive measures against viral infections, including trials for vaccines targeting CMV, yellow fever, and mpox.

Vaccine Development
Viral Prevention
Immunization Studies

Focus on developing and evaluating new vaccine formulations and delivery methods.

03 Autoimmune Conditions

Research investigating treatments for inflammatory bowel diseases and multiple sclerosis, including innovative approaches like fecal microbiota transplantation.

Crohn's Disease
Ulcerative Colitis
MS Treatment Strategies

Exploring novel therapeutic options and treatment de-escalation strategies.

04 Critical Care Medicine

Studies addressing postoperative care and management of severe conditions in intensive care settings, including burns and immune suppression.

Post-Surgery Care
Burn Treatment
ICU Interventions

Evaluating new approaches to improve patient comfort and outcomes in critical care.

Back to France All countries